Advancing CAR T & TCR Therapies in a More Disciplined Era of Cell Therapy Development
The global cell and gene therapy (CGT) field is entering a new phase of maturity. As CAR T and TCR technologies move beyond early clinical proof of concept, teams are facing tougher questions around clinical differentiation, scalable manufacturing, regulatory readiness, and long term commercial viability.
In this evolving landscape, success increasingly depends on precision targeting, robust CMC strategies, advanced analytical development, and clinically meaningful data across both hematologic and solid tumor indications. It is against this backdrop that the 11th CAR TCR Summit returns as the most technically focused CAR T and TCR conference dedicated to engineered T cell therapies.
What’s New at the 11th CAR TCR Summit?
Four Content Specific Tracks for Maximum Relevance
This year’s meeting introduces four dedicated content tracks, each engineered to address the real world challenges facing today’s CAR T and TCR development teams.
These tracks are designed to align insights across research, clinical development, analytical development, CMC, and process development functions, helping organizations break silos and accelerate decision making across the pipeline. Attendees can expect focused discussion on CAR T target selection, T cell biology, translational strategy, and manufacturing robustness.
Three New Cell Therapy Bootcamps
To support both emerging programs and more advanced pipelines, the Summit introduces three new in depth bootcamps, offering deep technical dives into the fundamental pillars of CAR T and TCR success.
Bootcamp topics include:
- T cell biology and next generation CAR design, including in vivo CAR T strategies
- Delivery, safety, and toxicity management in engineered T cell therapies
- Automated and closed system manufacturing, digital integration, and scale up for commercial readiness
- Regulatory and investor ready positioning for CGT assets
These sessions are built to support teams tackling persistent challenges such as manufacturing consistency, cost of goods, and clinical differentiation.
Fresh Data & New Voices from Across the CAR T & TCR Ecosystem
The 11th CAR TCR Summit welcomes 25 new presenting companies, bringing fresh perspectives on CAR T manufacturing strategies, clinical trial design, TCR pipeline development, and platform innovation.
Attendees will also gain access to unpublished clinical data from leading institutions and developers including Fate Therapeutics, Precigen, the University of Pennsylvania, Eureka Therapeutics, and Overland Therapeutics. These data presentations cover key areas of industry focus, including:
- CAR T approaches to autoimmune disease
- Solid tumor CAR T strategies and overcoming the tumor microenvironment
- Multi targeted CAR T constructs and durability challenges
Senior Level Insight for Teams Advancing CAR & TCR Programs
With a 40% C suite speaker faculty, the Summit delivers strategic insight alongside deep technical content. This senior level representation ensures coverage of:
- Portfolio and pipeline decision making
- Platform prioritization and risk management
- Translational strategy alignment with commercial goals
- Investment and partnership readiness in the CAR T and TCR space
The result is a CAR T and TCR meeting that provides 100% relevant insight for organizations navigating a more selective and data driven cell therapy environment.
Download the agenda to explore the full program and see how this year’s Summit supports teams building the next generation of CAR T and TCR therapies.
Explore the Agenda
Get a front row seat to the latest cell therapy breakthroughs across autoimmune disease, solid tumors and novel modalities through data-driven technical presentations, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of cell therapy deals.
Join Biopharma Experts
Be part of the hottest conversations in this tailor-made forum for senior executives across all stages of CAR and TCR drug development and make critical connections during our dedicated networking sessions and CAR-TCR Connect drinks reception.